Cantor Fitzgerald Initiates Coverage on LeMaitre Vascular (NASDAQ:LMAT)

Equities research analysts at Cantor Fitzgerald started coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm set a “neutral” rating and a $96.00 price target on the medical instruments supplier’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 4.90% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target for the company. Barrington Research reiterated an “outperform” rating and set a $92.00 target price on shares of LeMaitre Vascular in a report on Friday, September 20th. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, JMP Securities increased their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $94.67.

LeMaitre Vascular Trading Up 0.3 %

LMAT opened at $91.52 on Tuesday. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $93.32. The business’s 50-day moving average price is $88.64 and its 200-day moving average price is $81.12. The company has a market cap of $2.05 billion, a P/E ratio of 60.61, a P/E/G ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.37 EPS. Equities research analysts forecast that LeMaitre Vascular will post 1.85 earnings per share for the current fiscal year.

Insider Activity

In related news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.79% of the stock is currently owned by company insiders.

Institutional Trading of LeMaitre Vascular

A number of hedge funds and other institutional investors have recently modified their holdings of LMAT. Conestoga Capital Advisors LLC boosted its stake in LeMaitre Vascular by 0.4% during the second quarter. Conestoga Capital Advisors LLC now owns 1,941,501 shares of the medical instruments supplier’s stock worth $159,747,000 after acquiring an additional 8,584 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after purchasing an additional 4,964 shares in the last quarter. Congress Asset Management Co. MA boosted its position in shares of LeMaitre Vascular by 12.0% in the 1st quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after purchasing an additional 71,411 shares in the last quarter. Driehaus Capital Management LLC grew its stake in shares of LeMaitre Vascular by 52.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after buying an additional 90,573 shares during the last quarter. Finally, Summit Creek Advisors LLC increased its position in LeMaitre Vascular by 0.6% during the 1st quarter. Summit Creek Advisors LLC now owns 229,936 shares of the medical instruments supplier’s stock valued at $15,259,000 after buying an additional 1,435 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.